Glycemic control and diabetes management in hospitalized patients in Brazil by Edson Moreira Jr et al.
METABOLIC SYNDROME
DIABETOLOGY & 
Moreira et al. Diabetology & Metabolic Syndrome 2013, 5:62
http://www.dmsjournal.com/content/5/1/62RESEARCH Open AccessGlycemic control and diabetes management in
hospitalized patients in Brazil
Edson Duarte Moreira Jr1,2,3*, Patricia Carvalho Balthazar Silveira1, Raimundo Celestino Silva Neves1,3,
Clodoaldo Souza Jr1, Zaira Onofre Nunes3, Maria da Conceição C Almeida3 and for the Brazilian Diabetes
Investigators’ GroupAbstract
Background: The importance of tight blood glucose control among outpatients with diabetes mellitus is well
established, however, the management of diabetes in the hospital setting is generally considered secondary in
importance. This study sought to assess glycemic control and diabetes management in adult patients admitted to
hospitals in Brazil.
Methods: A cross-sectional and nationwide survey was conducted from July 2010 to January 2012. Eligible cases
were 18 years of age or older, had a diagnosis of diabetes and a hospitalization length of stay ≥72 hours. Socio-
demographic information, hospitalization details, and data on diabetes diagnosis, management and treatment were
collected for all patients by chart review. Information on all blood glucose (BG) readings for a maximum of 20
consecutive days of hospitalization was recorded for each patient.
Results: Overall, 2,399 patients were surveyed in 24 hospitals located in 13 cities from all five Brazilian regions. The
prevalence of patients presenting hyperglycemic (BG >180 mg/dL) or hypoglycemic (BG <70 mg/dL) events was
89.4% and 30.9% in patients in general wards, and 88.2% and 27.7% in those in Intensive Care Units (ICUs),
respectively. In addition, a BG measure >180 mg/dL was recorded in two-thirds of the patient-days. A high
proportion of patients were treated with sliding-scale insulin regimen alone in the general wards (52.0%) and in the
ICUs (69.2%), and only 35.7% and 3.9% received appropriate insulin therapy in general wards (basal + bolus insulin)
and in ICUs (continuous IV insulin), respectively.
Conclusions: Inpatient glycemic control and diabetes management needs improvement. Opportunities to improve
care in Brazilian hospitals include expanded use of intravenous insulin and subcutaneous basal-bolus insulin
protocols, avoiding use of sliding-scale insulin alone, increased frequency of blood glucose monitoring, and
institution wide quality improvement efforts targeting both physician and nursing behavior.
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The importance of tight blood glucose control among
outpatients with type 1 and 2 diabetes mellitus is well
established [1,2]. Over the past years, there has been
increased attention to inpatient glycemic control, as
evidenced by numerous reports published in the med-
ical community [3-5]. Compelling evidence continues* Correspondence: edson@bahia.fiocruz.br
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reproduction in any medium, provided the orto accumulate suggesting that poorly controlled blood
glucose levels among inpatients are associated with in-
creased morbidity and mortality, as well as with higher
health care costs [6-9]. In the past decade, studies have
focused attention to the possibility that hyperglycemia
in the hospital is not necessarily a benign condition
and that aggressive treatment of diabetes and hypergly-
cemia may result in reduced mortality and morbidity
[10-12]. In fact, hyperglycemia is a strong predictor of
adverse clinical outcome in a range of diseases such as
acute stroke [13,14], congestive heart failure [15,16],
community acquired pneumonia [17], acute myocardiall Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion [20].
Based upon these findings, the American College of
Endocrinology (ACE) and the American Diabetes Asso-
ciation (ADA) have published guidelines recommending
tight glucose control for inpatients with diabetes [21,22].
They also recommended the use of continuous insulin
infusion given through a standardized protocol as the
approach to control hyperglycemia in critically ill inpa-
tients. For noncritical ill diabetic inpatients, they sug-
gested the use of specific insulin regimens with combined
basal and short-acting insulin and appropriate bedside
glucose monitoring, avoiding the use of sliding-scale insu-
lin (fast or rapid-acting insulin in response to hyper-
glycemia) alone. More recently, studies showing that
intensive glucose control for critically ill patients is associ-
ated with severe hypoglycemia and/or increased mortality
[4,5,23] have led to less stringent recommendations
[7,24-26]. Research assessing inpatient glycemic control
state after the development of these guidelines has shown
that control is still poor and needs improvement [3,27,28].
The Brazilian Diabetes Society has endorsed the AACE/
ADA recommendations on inpatient glucose control [29],
but information about the epidemiology of diabetes and
glycemic control in Brazil is scarce. According to a study
performed by the Brazilian Ministry of Health in 1992
[30], diabetes was the fifth most common reason for
hospitalizations and ranked among the ten major causes
of mortality. Moreover, in a large multicenter survey in
Brazil, the prevalence of inadequate glycemic control of
outpatients with type 1 or type 2 diabetes was 90% and
73%, respectively [31]. Thus, outpatient diabetes man-
agement is a major problem in Brazil, with an impact on
public heath comparable to that in other countries
worldwide [32-35]. Knowledge on current state of in-
patient glycemic control in Brazil is essential for plan-
ning healthcare programs targeting improved diabetes
control. The purpose of this study was to describe gly-
cemic control and diabetes management in hospitalized
patients in Brazil.
Methods
This cross-sectional and nationwide survey was con-
ducted in Brazil from July 2010 to January 2012. It was
designed to portray glycemic control and diabetes man-
agement in a sample of adult patients admitted to hospi-
tals in Brazilian urban areas. Study design and reporting
format are in accordance with the recommended STROBE
(Strengthening the Reporting of Observational Studies in
Epidemiology) guidelines [36].
Site selection
Patients were surveyed in hospitals located in 13 cities
belonging to all five Brazilian regions, as follows: Southeast(Belo Horizonte, Botucatu, Marilia, Rio de Janeiro and São
Paulo), South (Campina Grande do Sul, Caxias do Sul,
Curitiba, Porto Alegre), Mid-west (Brasília), Northeast
(Salvador and Fortaleza) and North (Belém). For the site
selection, we identified in each of the participating cities a
list of candidate hospitals, to be chosen from those with
longer experience in clinical research and epidemiological
surveys. Each participating medical center had to be a
general hospital, medium to large size (>50 beds), with
registry of primary and secondary diagnosis for all inpa-
tients (preferably in an electronic database), and had to
have medical chart archives accessible to study data col-
lectors in order to gather information from patient
charts. According to these criteria, 30 hospitals were in-
vited to participate in the study. Twenty four accepted
and six declined for administrative reasons. Hospitals
joining the study were classified as academic (7), public
(6), or private (11).
Study population
Patients who met the eligibility criteria were consecu-
tively included in the study in reverse chronological
order proceeding back in time until the target number
of patients per site was reached. Eligible patients had to
be ≥18 years of age, have a known diagnosis of diabetes
(type 1 or type 2) either prior to admission or during the
hospitalization, and have a 72-hour or longer length of
stay in the hospital. Patients who had been admitted for
diabetic ketoacidosis, hyperosmolar hyperglycemic state
or gestational diabetes, who had a history of pancreatic
transplant, or patients on hospice or palliative care dur-
ing hospital admission were not included. Each hospital
was asked to enroll at least 80 and no more than 120 pa-
tients. The study protocol was approved by Ethical Review
Boards in each respective city.
Data collection
Socio-demographic information, hospitalization details,
and data on diabetes diagnosis, management and treat-
ment (type and route of insulin administration) were
collected for all patients by chart review using a struc-
tured questionnaire. Information on all blood glucose
(BG) readings for a maximum of 20 consecutive days of
hospitalization was recorded for each patient. Measure-
ment day 1 was defined as the day of admission for cases
with previously known diabetes or as the day of diag-
nosis for patients diagnosed with diabetes during the
hospitalization. Glucose measurements were recorded
for each measurement day as available, both bedside (ca-
pillary blood glucose) and laboratory serum glucose
values were utilized. Appropriate insulin therapy was de-
fined as scheduled subcutaneous insulin that delivers
basal, nutritional, and correction (supplemental) compo-
nents for non-critically ill patients and as continuous
Table 1 Selected characteristics (%) of 2,399 hospitalized









<30 2.3 0.2 1.9
30 – 39 3.5 1.7 3.2
40 – 49 10.7 5.4 9.7
50 – 59 22.7 22.2 22.6
60 – 69 27.2 31.3 28.0
≥70 33.5 39.2 34.6
Sex
Male 53.7 57.2 54.4
Female 46.3 42.8 45.6
Region
Southeast 46 38 44
South 23 11 21
Northeast 19 8 17
Midwest 8 43 15
North 4 0.4 3
Hospital type
Private 43 57 46
Academic 31 27 30
Public 26 16 24
Health information
Body mass index (Kg/m2)
Underweight (<18.5) 2.6 0.8 2.2
Normal weight (18.6 – 24.9) 31.5 24.7 30.0
Overweight (25.0 – 29.9) 33.5 38.7 34.6
Obese (30.0 – 39.9) 29.0 31.7 29.6
Morbidly obese (≥40.0) 3.4 4.1 3.6
Diabetes type
Type 1 9.5 3.7 8.3
Type 2 55.1 62.7 56.5





None 8.9 12.8 9.6
Oral medications only 36.5 42.5 37.7
Insulin only 18.6 12.2 17.3
Insulin and oral medications 11.2 7.8 10.5
Information not found in the
chart
24.8 24.7 24.9
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hemoglobin (A1C) values were included if they were
recorded during the first week of hospitalization or
within 30 days prior to admission. A team of study
nurses (not part of the hospital staff ) was hired and
trained for the data collection by one of the investigators
(EDM) at each study site. They were given orientation
on the protocol and specific details concerning data ab-
straction, and received technical and content support
during the study by the study staff. In addition, a hos-
pital questionnaire was also completed at each site,
collecting information on whether the blood glucose
measures and insulin administration were recorded in
the same form, existence of a protocol for the treatment
of hypoglycemia, existence of a mandatory protocol of
intravenous insulin infusion for intensive care unit
(ICU) patients, and whether the hospital had endocrin-
ology/diabetes team and/or ward.
Statistical analysis
We employed two analytic approaches for reporting BG
levels. One approach, the patient-day approach, grouped
BG levels by calendar day for each patient, and then cal-
culated a mean BG level for each patient-day. The other
one, the patient approach, employed each patient’s mean
BG level for the entire hospitalization as a single data
point. For each of these approaches, some of the follow-
ing performance measures were calculated: mean BG
level, median BG level and the percentage of BG levels
that fell within a predefined “optimal” range (80–139
mg/dL), stratified by location (general ward or ICU).
Hypoglycemic (BG <70 mg/dL) and hyperglycemic
(BG >180, >200 or >300 mg/dL) event rates were also
determined. Statistical analyses were performed with Stata
version 10 (Stata Corporation, College Station, TX).
Results
A total of 2,399 patients was surveyed in 24 hospitals
(11 private, 7 academic and 6 public) located in 13 cities
from all five regions in Brazil. Our sample was com-
prised by a higher proportion of males than females.
The age distribution was skewed towards the older cat-
egories, as nearly two-thirds of the subjects were age 60
years or older (Table 1). The Southeast and South re-
gions contributed more patients to the study, while the
North and Mid-west regions contributed fewer patients,
resembling the demographic distribution of population
in Brazil. Most patients had diabetes type 2 and the in-
formation on diabetes type was missing in over one third
of the patients. Diabetes had been diagnosed prior to ad-
mission in nearly all patients (98.7%). In regard to pread-
mission diabetes medication regimen, oral antidiabetic
drugs were the most common treatment reported (37.7%),
followed by insulin alone (17.3%), and approximately one-
Table 1 Selected characteristics (%) of 2,399 hospitalized
patients with diabetes in Brazil, 2010-2012 (Continued)
Mean hospital length of stay
(days)
14.9 13.2 14.6




Discharged 94.2 85.5 92.6
Transferred 1.7 6.8 2.7
Died 4.1 7.7 4.8
Consulted with a diabetes
specialistb
12.9 3.5 11.1
aIncludes only patients diagnosed with diabetes prior to admission (n=2,367).
bWithin a 3-day period after hospital admission.
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and median hospital lengths of stay were 14.6 and 10 days,
respectively. In general, endocrine/diabetes consultation
was infrequent, and patients in general wards were more
likely to have such consultation than those in ICUs
(Table 1).
Hospital performance of recommended diabetes care
measures according to location (general ward or ICU) is
shown in Table 2. Physician documentation of diabetes
history was recorded in more than 95% of the medical
charts, but 16% or less had an A1C assessment docu-Table 2 Diabetes management of 2,399 hospitalized






Physician documentation of diabetes
history in medical record
95.4a 97.0
HbA1C assessment documented for
diabetes patientsb
16.0 11.0
Blood glucose measured within 8 hours of
admission or diabetes diagnosis
31.2 47.1
Blood glucose monitored at least four
times daily (by patient-days)
55.2 61.2
Diabetes treatment
Sliding-scale insulin only 52.0 69.2





Continuous IV insulin 0 3.9
Other insulin regimen 3.6 3.5
Oral agents only 4.8 1.3
Diet only 3.9 1.0
aPercent.
bMeasured during first week of hospitalization or within 30 days prior to admission.
cScheduled subcutaneous insulin (basal, nutritional, and correction components).mented. Laboratory glucose assessment within 8 hours of
hospital admission for diabetes patients was low in both
general wards (31.2%) and ICUs (47.1%), and BG monitor-
ing at least 4 times daily occurred in only 55.2% to 61.2%
of patient-days. A relatively high proportion of patients
were treated with sliding-scale insulin regimen alone in
the general wards (55.2%) and in the ICUs (61.2%), only
35.7% and 3.9% received appropriate insulin therapy in
general wards and in ICUs, respectively (Table 2).
Measures used to assess the quality of glycemic con-
trol in hospitalized patients are presented in Table 3.
The percentage of early morning BG readings ≤180 mg/dL
on measurement day 3 was not sufficiently high for pa-
tients in general wards (54.7%) and in ICUs (62.8%). The
prevalence of any hyperglycemic (BG >180 mg/dL) or
hypoglycemic events (BG <70 mg/dL) was 89.4% and
30.9% in patients in general wards, and 88.2% and 27.7%
in those in ICUs, respectively. In addition, a BG mea-
sure >180 mg/dL was recorded in about two-thirds of the
patient-days, and approximately half of the patient-days
had at least one BG value greater than 200 mg/dL. When
the threshold was raised to 300 mg/dL, the percentage of
any hyperglycemic events ranged from 21.1% of patient-
days in general wards to 16.4% in ICUs. The percentage of
patient-days with any BG value <70 mg/dL was relatively
low in general wards (6.7%) and in ICUs (4.9%). Overall,
the percentage of patient-days with BG values within a
predefined “optimal” range (80-139 mg/dL) was only
11.8% in general wards and 15.0% in ICUs. The mean per-
centage of glucose readings >180 mg/dL by patient stay
(entire hospitalization) was 40.2 % in general wards and
34.9% in ICUs, while the mean percentage of glucose
readings <70 mg/dL by patient stay was 2.1% and 1.6%, re-
spectively. The morning glucose mean by patient-day was
162 mg/dL in general wards and 158 mg/dL in ICUs, and
the median was 141 mg/dL and 143 mg/dL, respectively
(Table 3).
Characteristics of diabetes management in participating
hospitals stratified by type: academic, public or private are
shown in Figure 1. All academic hospitals had an endo-
crinology/diabetes team compared to 71% and 64% of
public and private hospitals, respectively. A mandatory IV
insulin protocol was established at the ICU in most public
(83%) and private (82%) hospitals, while in only 17% of
the ICU in academic hospitals. About half of the hospitals
had all point-of-care blood glucose values and insulin
doses for a patient listed together on one flow sheet. Simi-
larly, roughly half of the hospitals had an established
protocol to treat hypoglycemic events.
Discussion
To our knowledge, this is the first multicenter, nation-
wide survey to describe glycemic control and diabetes
management in hospitalized patients in Brazil. Overall,
Table 3 Measures of glycemic control in 2,399 hospitalized patients in Brazil, 2010-2012.
General ward Intensive care unit (ICU)
Number of patients 1,934 465
% of BG on morning of D3 ≤180 mg/dL 54.7 62.8
% of patients with any BG >180 mg/dL 89.4 88.2
% of patients with any BG <70 mg/dL 30.9 27.7
Mean % glucose readings >180 mg/dL analyzed by patient stay (SD) 40.2 (27.6) 34.9 (26.1)
Mean % glucose readings <70 mg/dL analyzed by patient stay (SD) 2.1 (4.5) 1.6 (3.3)
Number of patient-days 18,887 4,227
% of patient-days with any BG >180 mg/dL 64.7 61.3
% of patient-days with any BG >200 mg/dL 55.8 52.1
% of patient-days with any BG >300 mg/dL 21.1 16.4
% of patient-days with any BG <70 mg/dL 6.7 4.9
% of patient-days with all BG within target range (80–139 mg/dL) 11.8 15.0
% of patient-days with mean BG within target range (80–139 mg/dL) 30.0 32.4
Mean of morning BG analyzed by patient-day (SD) 162 (78) 158 (66)
Median of morning BG analyzed by patient-day 141 143
BG = fingerstick blood glucose; D3= measurement day 3; SD= standard deviation.
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included in our survey was poor. There were several defi-
ciencies in the glycemic control and diabetes management
of hospitalized patients in our study. These deficiencies
were both in processes of care (e.g., limited use of basal
and bolus insulin) and in outcomes (i.e., glycemic control)
compared to current recommended guidelines [7,24]. We
observed only 11.8%-15.0% of patient-days with mean BG
levels between 80-139 mg/dL, though Goldberg et al. [37]Figure 1 Selected characteristics of hospitals (n=24) by type: academhave proposed 85% of patient-days with mean BG levels
within this range as a “gold standard” for inpatient gly-
cemic control.
The target of maintaining all glucose values ≤180 mg/dL
recommended in the ADA/AACE guidelines for hospital
diabetes management was not generally achieved [7,24].
The mean rate of hyperglycemia (BG>180 mg/dL) per pa-
tient was higher than previously reported in a survey at a
large teaching hospital in the US (40.2% vs. 31%) [27].ic, public or private, Brazil, 2010-2012.
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one BG measure above 180 mg/dL. Although hypergly-
cemia was common, hypoglycemia was relatively infre-
quent. This should be interpreted with caution, and may
be a consequence of insufficient insulin regimens and
loose glycemic control rather than an indication of good
glycemic management, as suggested by the high rates of
hyperglycemia.
Most ICUs in private or public hospitals had a
mandatory IV insulin protocol established, as opposed
to those in academic hospitals. Nonetheless, overall, very
few patients in the ICUs were treated with continuous
IV insulin. Thus, suggesting that establishment of an IV
insulin protocol is not sufficient and does not guarantee
its use will be necessarily mandatory. Failure to provide
comprehensive training of ICU personnel about the
protocol, lack of appropriate equipment or adequate
glucose monitoring, and low awareness regarding the
importance of glycemic control are among the potential
barriers to implementing a mandatory IV insulin protocol.
In addition, more than half of the hospitals in our study
had not established a hypoglycemia treatment protocol
yet. Poor quality of diabetes care and non-existence of
glycemic management guidelines/protocols indicate that
there remains potential for substantial improvements
in diabetes care in hospitalized patients in Brazil.
Formal communication among various professionals
and services as well as appropriate training can garner
support from health care providers for new practices and
protocols.
Appropriate insulin therapy was given to no more than
one third of inpatients with diabetes in our study. Basal
insulin was prescribed for only 5.9% of patients, as com-
pared to 43% for patients in a previous survey [27].
Moreover, most patients with diabetes in our survey re-
ceived sliding-scale insulin regimen alone, even though
it has been shown that sliding-scale insulin by itself is
associated with poor inpatient glycemic control and even
deleterious effects [38]. In a study of 999 patients with
known diabetes treated in 44 hospitals across the U.S.,
16% percent of patients with type 1 diabetes and 35% of
patients with type 2 diabetes (using insulin as outpa-
tients) were treated with sliding-scale insulin alone [39].
Possible barriers to adherence to the recommended
standards and optimal diabetes care in our study include
a fragmented delivery system, the lack of a system that
facilitate the appropriate use of scheduled insulin therapy
and low institution support for inpatient multidisciplinary
team training.
In regard to performance of recommended hospital
diabetes care practices [7,24], there was also evidence for
an immediate need for improvement. Few patients had
information regarding diabetes type and preadmission
medication regimen recorded on their medical charts,and even less patients had an A1C measurement regis-
tered during the first week of hospitalization or within
30 days prior to admission. Thus, indicating poor quality
of data recording and the need to improve practices and
training of health care personnel. Two-thirds of inpa-
tients with diabetes did not have their blood glucose
measured within 8 hours of their hospital admission,
and in only 55%-61% of the patient-days the BG was mon-
itored at least four times per day. In contrast, a study
conducted on 1,718 patients with a history of diabetes in
thirty-seven US academic medical centers found that 31%
had an A1C measurement, 77% had a laboratory blood
glucose result recorded within 8 hours of hospital admis-
sion, and 81.3% had blood glucose monitored at least 4
times on the second day of hospitalization [3].
Insulin-use safety in the hospital setting has recently
become a goal to quality improvement efforts [40-42].
Future research should focus on strategies to improve glu-
cose control, as well as on patient, clinician, and system
barriers to improving inpatient glycemic management,
while enhancing the safe use of insulin in this setting. Fac-
tors such as competing priorities and limited resources,
skepticism about the benefits of tight inpatient glycemic
control, fear of hypoglycemia, inadequate knowledge and
understanding of diabetes, hyperglycemia, and appropriate
management of blood glucose levels may play an import-
ant role in hospital settings similar to ours.
Strengths and limitations
Strengths of this study include its data collection
methods with rigorous inclusion criteria, collection of
detailed glycemic data by a team of non-staff trained
personnel, and use of various statistical approaches to
more accurately assess glycemic control. We also in-
cluded a large sample of inpatients from private, public
and academic hospitals located in all five Brazilian re-
gions. Despite this, there are some limitations to this
study. The data are retrospective and only a limited
number of clinical variables could be assessed for each
patient. There could also have been differences in the
frequency of glucose measurement depending on treat-
ment, which can potentially bias estimated prevalence of
hyperglycemia and hypoglycemia. We also did not have
a practical method to assess nutritional status or the ad-
equacy of insulin dosing over time for each patient.
Conclusions
Our results indicate that inpatient glycemic control and
diabetes management still needs much improvement,
despite the evidence of the hazards of inpatient hyper-
glycemia and the publication of specialist consensus
guidelines on inpatient glucose management in the past
decade. Opportunities to improve care in Brazilian hospitals
include expanded use of intravenous insulin, subcutaneous
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increased frequency of blood glucose monitoring, avoiding
use of sliding-scale insulin by itself, and institution wide
quality improvement efforts targeting health care person-
nel behavior.
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